Shares of Cencora Inc. (NASDAQ:COR) are trading lower on Wednesday as the company reported its fiscal 2026 second-quarter results and lowered its annual guidance.
Cencora Earnings Report Drives COR Selloff
The pharmaceutical solutions organization reported second-quarter adjusted earnings of $4.75, missing the consensus of $4.81.
Sales of $78.36 billion came in below the expectation of $81.09 billion.
Sales increased 3.8% year over year, primarily due to a 2.9% increase in revenue within the U.S. Healthcare Solutions segment and a 13% increase in revenue within the International Healthcare Solutions segment.
data-variant=”card”
data-news-mode=”manual”
>
Read Also:
Cencora CFO Jim Cleary To Retire After Years Of Driving Growth